GEO DataSets

(Submitter supplied) CD20 is a clinically validated target for Non-Hodgkin’s lymphomas and autoimmune diseases. Interactions of CD20 with the B cell receptor (BCR) and components of the BCR signaling cascade have been reported. In this study we show that antibodies against CD20 or activation of the BCR by specific antibodies induce very similar expression patterns of up- or down-regulated genes in NHL cell lines indicating that CD20 may play a role in BCR signaling and vice versa. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4982

Platform:

GPL570

96 Samples

Download data: CEL, XLS

Analysis of NHL lines treated with CD20 or B-cell receptor (BCR) antibodies. CD20 is a B cell-specific, cell surface protein; BCR has a key role in B cell development. Results provide insight into concordance in molecular changes following BCR activation and anti-CD20 Ab treatment in lymphoma cells.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 8 agent, 4 cell line sets

Platform:

GPL570

Series:

GSE23394

96 Samples

Download data: CEL

(Submitter supplied) CD20 is an integrate membrane protein expressed on the surface of normal and malignant B-cells. It is an excellent molecular target for monoclonal antibodies (mAbs) that are widely used in the treatment of non-Hodgkin’s lymphomas (NHL) and chronic lymphocytic leukemia (CLL). Anti-CD20-directed therapies are the most effective, successful and widely used therapeutic monoclonal antibodies, routinely incorporated into all phases of conventional treatment, including first-line, maintenance and salvage treatment. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL16699

8 Samples

Download data: TXT

(Submitter supplied) We investigated the differential regulation patterns of type I anti-CD20 monoclonal antibody (mAb) rituximab and type II obinutuzumab on a transcriptional level. Using a panel of MCL cell lines, we determined the effects of obinutuzumab and rituximab as monotherapies as well as in combination on cell viability and proliferation. Obinutuzumab induced a higher reduction in cell proliferation in each mantle cell lymphoma cell line than rituximab did. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

75 Samples

Download data: CEL